Makei V

Gynecological tumors / Breast cancer, Pediatric oncology/hematology
Germ cord stroma tumor, Solid tumors
other systemic therapies
A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).
A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).